The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Genomic testing for lung cancer in the UK
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, comments on the state of genomic testing non-small cell lung cancer (NSCLC). The Genomic Test Directory for Cancer implemented by Genomic Laboratory Hubs (GLHs) in England have enabled the detection of at least 8 genes via next-generation sequencing (NGS) of DNA and RNA. This allows patients to access targeted therapies and Prof. Popat highlights the need to be aware of the latest therapies that may be available via alternative licensing schemes such as Project Orbis. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
